Navigation Links
Studies Investigate New Methodologies to Improve Recovery and Survival Strategies for Patients Undergoing Hematopoietic Cell Transplantation
Date:12/10/2011

demonstrated recently by using a less aggressive, non-myeloablative preparative regimen, followed by an infusion of unmanipulated bone marrow and the post-transplant use of a common chemotherapy drug, cyclophosphamide (Cy), but relapse is relatively common, especially in those with high-risk myeloid malignancies. This study sought to determine whether it is possible to decrease the probability of relapse in these high-risk patients by using a myeloablative preparative regimen with PBSCs, instead of bone marrow, as the graft source.

Between January 2009 and March 2011, the investigators initiated a clinical trial enrolling 20 patients with high-risk blood cancers, including leukemia and both Hodgkin and non-Hodgkin lymphoma, undergoing haploidentical HCT. Participants were eligible for the trial if they were perceived to be at a high risk of relapse using a less aggressive preparative regimen following transplantation. Eleven patients (55%) had relapsed or refractory disease, while the remaining nine patients (45%) had standard-risk disease, the majority being leukemia patients in remission but associated with poor-risk features. After the administration of the myeloablative preparative regimen, patients underwent transplantation with PBSCs, followed by an immunosuppressive regimen of Cy (50mg/kg/day) on days three and four post transplant along with other supportive therapies.

After an average follow-up of 14 months, investigators reported an estimated one-year overall survival rate of 74 percent and a disease-free survival (DFS) rate of 51 percent for all patients; for standard risk patients, one year overall survival was 100 percent and DFS was 76 percent. Non-relapse mortality at 100 days and 12 months was 10 percent for all patients and zero for standard risk patients. The cumulative incidence of chronic GVHD at one year was 42 percent.

Non-infectious fever developed in 90 percent of patients within a median of 2.5 days of transplant and w
'/>"/>

SOURCE American Society of Hematology
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Bayers Drospirenone-containing Combination Oral Contraceptives: FDA Advisory Committees Affirm Positive Benefit-risk Profile and Recommend an Update of Labels to Reflect Information From Available Studies
2. Genomic Health Announces Presentation of Sixteen Oncotype DX Studies at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium
3. Montage Announces Three More Hospitals Implement Their On-Demand Search and Data Mining Technology for Radiology Studies
4. Sustained Viral Response from Phase 2 Studies of BI 201335, Including Difficult-to-Treat HCV Patient Types
5. Isis Initiates Phase 1 Studies with Isis-GCGRRx and Isis-GCCRRx to Treat Type 2 Diabetes
6. Data From Phase 2 Clinical Studies of Telotristat Etiprate in Patients With Carcinoid Syndrome to be Presented at North American Neuroendocrine Tumor Society Meeting
7. New Clinical Studies Presented at the American Society of Anesthesiologists Annual Meeting Show Benefits of Masimo Noninvasive Technologies: SpHb, PVI, RRa, and SEDLine
8. Inovio Pharmaceuticals and VGX International to Advance Therapeutic Hepatitis C and Hepatitis B Synthetic Vaccines into Clinical Studies
9. Managing Bioequivalence Studies to Optimize the Quality, Cost, and Speed of Generics Manufacturing
10. FDA Seeks Comment on Proposed Guidelines for High-Quality Clinical Studies
11. Urgent® PC Clinical Studies Results Scheduled for Presentation at International Continence Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Rose, baseball,s all-time hits leader, is the new spokesperson for ... Pharma has announced. "Pete,s a Hall of Famer ... on board with Myoflex," said Ducere Pharma Chief Executive Officer ... is known across all generations. The passion and intensity that ...
(Date:1/23/2015)... 2015  Now available for sale, The Armor1 Ankle Roll ... ankle sprains by cushioning the ankle from an inversion ... the outside of any shoe type and allows the ... offering protection against sprains. With customers in physical therapy, ...
(Date:1/23/2015)... SETAUKET, N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, ... where its Phase I trial of Lixte,s lead compound, LB‑100, ... institutions. John S. Kovach , M.D., the ... was planned to be completed at a single site. Accrual ...
Breaking Medicine Technology:Pete Rose bets on Myoflex to relieve aches and pains 2The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... WALTHAM, Mass. , March 22 Interleukin Genetics, Inc. (NYSE ... the NYSE Amex LLC (the "Exchange") has granted the Company an extension ... will remain listed up to June 23, 2010 , subject to ... towards the Company,s plan to regain compliance. , ...
... and Manufacturers of America (PhRMA) issued the following statement today on passage of comprehensive health care reform and accompanying reconciliation legislation in the U.S. House of Representatives: , ... , ... ... ...
Cached Medicine Technology:NYSE Amex Provides Interleukin Genetics, Inc. Extension To Meet Continued Listing Standards 2NYSE Amex Provides Interleukin Genetics, Inc. Extension To Meet Continued Listing Standards 3PhRMA Statement on Health Care Reform 2PhRMA Statement on Health Care Reform 3PhRMA Statement on Health Care Reform 4PhRMA Statement on Health Care Reform 5
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue Cross) wants ... “Live Fearless.” , The “Faces of Fearless” campaign ... how they or someone they know has faced a challenge, ... moment. By telling these types of stories through livefearlessmn.com, participants ...
(Date:1/22/2015)... January 22, 2015 Thousand of GranuFlo ... Care recalled its GranuFlo and NaturaLyte dialysis concentrates continue ... in U.S. District Court, District of Massachusetts, Bernstein Liebhard ... the Court has remanded a case filed by the ...
(Date:1/22/2015)... January 22, 2015 A study ... Medicine flagship journal Medicine & Science in Sports ... exercise may help reduce gastrointestinal (GI) problems associated ... , Participants in the double-blind, placebo-controlled study took ...
(Date:1/22/2015)... 22, 2015 Payday lending practices in ... and cause financial distress to the states that permit ... Howard University’s Center on Race and Wealth. , While ... activity, payday loans at the same time substantially depress ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Lower-Auto-Insurance.com has released a ... kit in a car for reducing the costs of an ... will also be able to get lower prices for their vehicle ... an important role in determining policy costs. Because of this, ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... MEDmarketplace.com announced today that it has been awarded a ... contracting entity for the Sisters of Mercy Hospital System ... marketplace for selling surplus medical equipment and supplies. ... the agreement, Mercy,s 18 acute care hospitals, two heart ...
... CHICAGO, Dec. 4 The Neurologic & Orthopedic Hospital of,Chicago ... Chicago,Red Stars, a charter member of Women,s Professional Soccer, a ... world. The NOHC will,also be an official partner of ... , Heading the medical ...
... format for its “OneMedForum 2009” finance conference, ... San Francisco at the Sir Francis Drake ... disrupters” affecting each of the following medtech ... and Neurostimulation; Cardiology; Urology and Sexual Health; ...
... Kenneth K. Westbrook, a leading executive in Southern ... Chief Executive Officer of Integrated Healthcare Holdings, Inc., effective ... hospitals in Orange County, California: Western Medical Center -- ... Center and Coastal Communities Hospital. , ...
... blood pressure does not improve a common form of ... international study. , The study, which included researchers ... leadership positions, appears in this week,s issue of the ... , The findings are disappointing to researchers, who continue ...
... programs to help consumers make informed health care decisions , ... While data indicates that area doctors are doing a ... health of their employees, none of this matters if consumers ... to research released today by the Dallas-Fort Worth Business Group ...
Cached Medicine News:Health News:MEDmarketplace.com Signs Contract with Resource Optimization & Innovation (ROi) to Sell Surplus Hospital Equipment 2Health News:MEDmarketplace.com Signs Contract with Resource Optimization & Innovation (ROi) to Sell Surplus Hospital Equipment 3Health News:Neurological & Orthopedic Named Official Hospital of Chicago Red Stars Women's Pro Soccer Team 2Health News: OneMedPlace announces panels for "OneMedForum 2009: Disrupters and Drivers in Eight Areas of Medical Technology" -- CEOs and investors to meet in unique format of focused sessions 2Health News:Integrated Healthcare Holdings, Inc. Announces New Chief Executive Officer 2Health News:Study finds treatment fails to improve common form of heart failure 2Health News:Study finds treatment fails to improve common form of heart failure 3Health News:Partnership for Peak Healthcare Performance Research Shows Consumers' Lack Involvement in Managing Their Health 2Health News:Partnership for Peak Healthcare Performance Research Shows Consumers' Lack Involvement in Managing Their Health 3Health News:Partnership for Peak Healthcare Performance Research Shows Consumers' Lack Involvement in Managing Their Health 4
The Freedom Clear catheter is a 100% latex-free, self-adhering, one piece catheter with an ultra-thin sheath for every day wear....
... Natural® all-silicone non-adhesive male external catheter ... of latex-related allergic reactions. It is ... to change external catheters several times ... Natural catheter comes with an adjustable ...
Used as a percutaneous entry needle to introduce wire guides. The coaxial design reduces potential A.V. malformations. Supplied sterile in peel-open packages. Intended for one-time use....
... Used for stone manipulation ... urinary tract. Enhanced wire ... dilation in the ureter. ... easy, ergonomic one-handed operation. ...
Medicine Products: